CoreAge Rx vs Fifty 410
Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Fifty 410 head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 68 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
That doesn't make Fifty 410 a bad call — it's best for readers who want budget-focused buyers wanting transparent no-membership compounded glp-1 pricing. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Fifty 410 | |
|---|---|---|
| Brief Score | 94/100 (A) | 68/100 (C) |
| Semaglutide | $149/mo | From $99/mo (all doses, compounded) |
| Tirzepatide | $349/mo | From $133/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.
Fifty 410: New to the tracker on 1 August 2026. The published line reads From $99/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.